On May 22, 2021, the seventh academic annual meeting of the Hematology Branch of the Chinese Association of Traditional Chinese Medicine was held in Hangzhou, an international metropolis known as "three clouds and mountains and one city".

As one of the co-organizers of this conference, Mengyang Pharmaceutical invited clinical experts from all over the country who are committed to the multidisciplinary development of oncology and blood to gather in Hangzhou, held the "Chinese Medicine Diagnosis and Treatment Plan for Blood Diseases Implementation Forum" at the meeting, and officially launched the "Observation and Case Collection of the Efficacy of Shengbai Oral Liquid in the Prevention and Treatment of Leukopenia after Chemotherapy".

Professor Chen Xinyi, Chairman of the Conference and Chairman of the Hematology Branch of the China Association of Chinese Medicine, delivered a speech for the sub-forum. He pointed out that in order to better promote and apply the "diagnosis and treatment plan and path interpretation of dominant diseases in the treatment of blood diseases with traditional Chinese medicine" and meet the needs of clinical diagnosis and treatment, in 2021, the Hematology Branch of the China Association of Chinese Medicine launched the training work of path interpretation and the funding project of research topics. The convening of this sub-forum of Mengyang Pharmaceutical has played a good exemplary role and made a good start for the reasonable and compliant development of the branch's work. We also welcome more people of insight to join our Hematology Branch to do a better job in the prevention and treatment of tumors and tumor complications.

Then, Mr. Zhang Min, Chairman of Mengyang Pharmaceutical, delivered a speech for the conference, he introduced the positioning, development status and future planning of Mengyang Pharmaceutical Enterprise, and wished the conference a complete success。

In the academic exchange part, Professor Tian Shaodan from Dongzhimen Hospital of Beijing University of Chinese Medicine brought a wonderful sharing of "Interpretation of the Diagnosis and Treatment Plan and Path of Dominant Diseases in the Treatment of Blood Diseases with Traditional Chinese Medicine", which was jointly edited by the chairmen of the three major blood disease branches and 52 experts across the country, involving a total of 19 common diseases and symptoms of the blood system. She pointed out that the occurrence, progression or evolution of blood diseases is mainly based on false syndromes, and there are currently more than 40 kinds of therapeutic Chinese patent medicines on the market. Among them, there are not many proprietary Chinese medicines corresponding to prescription syndromes, drug certificates, and drug diseases, and there are not many proprietary Chinese medicines with win-win effects. In this regard, she focused on the new traditional Chinese medicine drug "Shengbai Oral Liquid", which has the highest frequency of drug recommendation by experts and has evidence-based medical evidence. It is evaluated as a new traditional Chinese medicine that is rapidly promoted in domestic clinical practice to replenish the kidney and marrow and actively generate whitening.

Subsequently, Professor Sun Tao from the East Hospital of Beijing University of Chinese Medicine made a report on "Sharing the Results of the Multi-center Clinical Study of Shengbai Oral Liquid Re-evaluation after Marketing". Studies have confirmed that Shengbai oral liquid can effectively reduce the incidence of neutropenia, especially the incidence of grade I and II neutropenia and leukopenia. In addition, it also has certain advantages in reducing the incidence of thrombocytopenia in peripheral blood. The experimental group was significantly better than the control group in the sub-items of the TCM symptom scale, including numbness, excessive urination, drowsiness, forgetfulness, fatigue (fatigue), sadness, phlegm, and cold intolerance, indicating that Shengbai oral liquid had certain advantages in improving symptoms. In terms of fatigue improvement, the improvement of overall fatigue and fatigue children in the experimental group was significantly better than that in the control group, indicating that Shengbai oral liquid had a good improvement effect on fatigue symptoms. Through the analysis of vital signs, physical examination, laboratory tests, electrocardiogram, concomitant medication and adverse events, it was shown that Shengbai oral liquid had a good safety profile in clinical application. Professor Sun Tao also pointed out that the culture of traditional Chinese medicine has a long history, broad and profound, and Shengbai Oral Liquid is constantly forging ahead while inheriting the essence, and has played a clinical advantage in the treatment of syndrome differentiation and prevention of diseases in many fields.

Then, Professor Chen Xinyi, consultant of the project of "Observation and Case Collection of the Efficacy of Leukopenia after Chemotherapy with Shengbai Oral Liquid", Professor Sun Tao, PI of the project, and Ms. Liu Limin, Vice President of Marketing of Mengyang Pharmaceutical, jointly took the stage and officially launched the project, and the meeting ushered in a climax in warm applause.

Finally, Ms. Liu Yu, product manager of Mengyang Pharmaceutical, gave a detailed interpretation of the project for everyone. So far, the forum on the implementation of the TCM diagnosis and treatment plan for hematological diseases has come to a successful conclusion.

The convening of this forum is not only a feast of academic exchanges, but also a new journey of multidisciplinary cooperation in the prevention and treatment of tumors, and it is also a big step for Mengyang Pharmaceutical to improve the quality of life of cancer patients, uphold the patient-centered, unmet clinical needs as the guide, keep the integrity and innovation, and continue to struggle!